The effect of angiotensin-converting enzyme inhibitor use on bone loss in elderly Chinese

Journal of Bone and Mineral Metabolism

Volumn 30, Issue 6, 2012, Pages 666-673

  Zhang, Ya Feng ^a,b   Qin, Ling ^b   Leung, Ping Chung ^b   Kwok, Timothy C Y ^b  

^a NANTONG UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiotenin converting enzyme inhibitor; Bone mineral density; Osteoporosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; STEROID;

AGED; ARTICLE; BODY WEIGHT; BONE DENSITY; CHINESE; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; FEMALE; FEMUR NECK; HIP; HONG KONG; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PRIORITY JOURNAL; SEX DIFFERENCE; SIDE EFFECT; WEIGHT CHANGE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ASIAN CONTINENTAL ANCESTRY GROUP; BONE DENSITY; BONE DISEASES, METABOLIC; COHORT STUDIES; FEMALE; FEMUR NECK; HUMANS; MALE; OSTEOPOROTIC FRACTURES; PELVIC BONES; SEX FACTORS;

EID: 84875804011     PISSN: 09148779     EISSN: 14355604     Source Type: Journal    
DOI: 10.1007/s00774-012-0363-3     Document Type: Article

References (28)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K et al (2008) Heart disease and stroke statistics-2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 117:e25-146
2. Cole ZA, Dennison EM, Cooper C (2008) Osteoporosis epidemiology update. Curr Rheumatol Rep 10:92-96
3. Vestergaard P, Rejnmark L, Mosekilde L (2009) Hypertension is a risk factor for fractures. Calcif Tissue Int 84:103-111
4. Peach MJ (1977) Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 57:313-370
5. Rejnmark L, Vestergaard P, Mosekilde L (2006) Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 24:581-589
6. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC (2005) Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 20:613-618
7. Liu YY, Yao WM, Wu T, Xu BL, Chen F, Cui L (2011) Captopril improves osteopenia in ovariectomized rats and promotes bone formation in osteoblasts. J Bone Miner Metab 29:149-158
8. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR (2004) Use of beta-blockers and risk of fractures. JAMA 292:1326-1332
9. Pérez-Castrillón JL, Silva J, Justo I, Sanz A, Martín-Luquero M, Igea R, Escudero P, Pueyo C, Díaz C, Hernández G, Dueñas A (2003) Effect of quinapril, quinapril-hydrochlorothiazide, and enalapril on the bone mass of hypertensive subjects: relationship with angiotensin converting enzyme polymorphisms. Am J Hypertens 16:453-459
10. Lynn H, Kwok T, Wong SY, Woo J, Leung PC (2006) Angiotensin converting enzyme inhibitor use is associated with higher bone mineral density in elderly Chinese. Bone 38:584-588
11. Masunari N, Fujiwara S, Nakata Y, Furukawa K, Kasagi F (2008) Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci 57:17-25
12. Lau EM, Leung PC, Kwok T, Woo J, Lynn H, Orwoll E, Cummings S, Cauley J (2006) The determinants of bone mineral density in Chinese men-results from Mr. Os (Hong Kong), the first cohort study on osteoporosis in Asian men. Osteoporos Int 17:297-303
13. Kwok T, Leung J, Zhang YF, Bauer D, Ensrud KE, Barrett-Connor E, Leung PC, Osteoporotic Fractures in Men (MrOS) Research Group (2011) Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men? Osteoporos Int Nov 12 [Epub ahead of print]
14. Inzerillo AM, Epstein S (2004) Osteoporosis and diabetes mellitus. Rev Endocr Metab Disord 5:261-268
15. Gerdhem P, Isaksson A, Akesson K, Obrant KJ (2005) Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 16:1506-1512
16. Dvorak MM, De Joussineau C, Carter DH, Pisitkun T, Knepper MA, Gamba G, Kemp PJ, Riccardi D (2007) Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone. J Am Soc Nephrol 18:2509-2516
17. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, HORIZON investigators (2009) Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373:1253-1263
18. Hatton R, Stimpel M, Chambers TJ (1997) Angiotensin II is generated from angiotensin I by bone cells and stimulates osteoclastic bone resorption in vitro. J Endocrinol 152:5-10
19. Shimizu H, Nakagami H, Osako MK, Hanayama R, Kunugiza Y, Kizawa T, Tomita T, Yoshikawa H, Ogihara T, Morishita R (2008) Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB J 22:2465-2475
20. Skeggs LT Jr, Kahn JR, Lentz K, Shumway NP (1957) The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 106:439-453
21. Erdös EG (1990) Angiotensin I converting enzyme and the changes in our concepts through the years. Lewis K. Dahl memorial lecture. Hypertension 16:363-370
22. Lerner UH, Jones IL, Gustafson GT (1987) Bradykinin, a new potential mediator of inflammation-induced bone resorption. Studies of the effects on mouse calvarial bones and articular cartilage in vitro. Arthritis Rheum 30:530-540
23. Lerner UH (1991) Bradykinin synergistically potentiates interleukin-1 induced bone resorption and prostanoid biosynthesis in neonatal mouse calvarial bones. Biochem Biophys Res Commun 175:775-783
24. Pitt B (1995) "Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 9:145-149
25. López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H, Tendera M, Waagstein F, Kjekshus J, Lechat P, Torp-Pedersen C (2004) Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology. Eur Heart J 25:1454-1470
26. Koshida H, Takeda R, Miyamori I (1998) Lisinopril decreases plasma free testosterone in male hypertensive patients and increases sex hormone binding globulin in female hypertensive patients. Hypertens Res 21:279-282
27. Kwok T, Ohlsson C, Vandenput L, Tang N, Zhang YF, Tomlinson B, Leung PC (2010) ACE inhibitor use was associated with lower serum dehydroepiandrosterone concentrations in older men. Clin Chim Acta 411:1122-1125
28. Ma YF, Stimpel M, Liang H, Pun S, Jee WS (1997) Impact of antihypertensive therapy on the skeleton: effects of moexipril and hydrochlorothiazide on osteopenia in spontaneously hypertensive ovariectomized rats. J Endocrinol 154:467-474